Literature DB >> 1573976

Tumor necrosis factor-alpha induces vascular hyporesponsiveness in Sprague-Dawley rats.

K Takahashi1, K Ando, A Ono, T Shimosawa, E Ogata, T Fujita.   

Abstract

The cytokine tumor necrosis factor-alpha (TNF alpha) is one of the major mediators of septic shock. Because vasodilation is a hallmark of sepsis and decreased vascular responsiveness has been implicated in the pathogenesis of septic shock, we studied the effect of TNF alpha on the mean blood pressure in conscious rats and vascular responsiveness to vasoconstrictors ex vivo using the standard organ bath method. Intravenous infusion of TNF alpha (0.006 or 0.06 mg/kg/hr for 10 hours) decreased mean blood pressure in a dose-dependent fashion. Contractile responses to norepinephrine were depressed dose-dependently in the aortic rings both with and without its endothelium. Aortic contractions by potassium depolarization were also depressed. These results suggest that TNF alpha induces non-specific vascular hyporesponsiveness, which is independent of the presence of the endothelium. The TNF alpha-induced vascular hyporesponsiveness might contribute to the hypotensive action of TNF alpha.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573976     DOI: 10.1016/0024-3205(92)90262-n

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction.

Authors:  Rob H P Hilgers; Dongqi Xing; Kaizheng Gong; Yiu-Fai Chen; John C Chatham; Suzanne Oparil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-07-09       Impact factor: 4.733

2.  Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; M Ferlito; G M Campo; M Arlotta; S Grimaldi; C Quartarone; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock.

Authors:  F Squadrito; S Guarini; D Altavilla; G Squadrito; G M Campo; M Arlotta; C Quartarone; A Saitta; D Cucinotta; C Bazzani; M M Cainazzo; C Mioni; A Bertolini; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock.

Authors:  C Thiemermann; C C Wu; C Szabó; M Perretti; J R Vane
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

5.  Role of cardiac- and myeloid-MyD88 signaling in endotoxin shock: a study with tissue-specific deletion models.

Authors:  Yan Feng; Lin Zou; Chan Chen; Dan Li; Wei Chao
Journal:  Anesthesiology       Date:  2014-12       Impact factor: 7.892

6.  Human lymphotoxin mutein lacks hypotensive activity but has higher in vivo antitumor activity than lymphotoxin or tumor necrosis factor.

Authors:  M Taniyama; T Morita; Y Yamagishi; A Kato; C Bando; N Okawa; A Kaji
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; P Canale; M Ioculano; G M Campo; L Ammendolia; M Ferlito; B Zingarelli; G Squadrito; A Saitta
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.